Literature DB >> 31367882

Interval Colorectal Cancer in Inflammatory Bowel Disease: The Role of Guideline Adherence.

Kristin E Burke1,2, Jennifer Nayor3, Emily J Campbell4, Ashwin N Ananthakrishnan5,6, Hamed Khalili5,6, James M Richter5,6.   

Abstract

BACKGROUND: Factors associated with interval colorectal cancer (CRC) development in the inflammatory bowel disease (IBD) population remain unclear. AIMS: Among a cohort of patients with interval CRC, we aimed to evaluate IBD characteristics, colonoscopy quality indicators, and surveillance guideline adherence.
METHODS: We performed a retrospective review of IBD- and non-IBD-associated interval CRCs diagnosed between January 2007 and December 2014 within a large US healthcare system. We evaluated risk factors for CRC among patients with IBD. We assessed adherence to surveillance guidelines according to the American Society for Gastrointestinal Endoscopy (IBD surveillance) and the US Multi-Society Task Force on Colorectal Cancer (polyp surveillance). We compared colonoscopy quality measures between patients with and without IBD.
RESULTS: Among 5345 cases of colonic adenocarcinoma, we detected 15 IBD-associated cases of interval CRC and 230 non-IBD-associated cases of interval CRC. Compared to patients without IBD, IBD patients were younger (54.5 vs. 70.4 years; p < 0.0001) and experienced a shorter interval between index colonoscopy and CRC diagnosis (20.7 vs. 35.1 months; p = 0.0009). Fifty three percent (8/15) of interval CRCs in IBD patients were detected within surveillance guidelines. All IBD patients with interval CRC detected after guideline surveillance interval had high-risk features, including active inflammation, previous low-grade or indefinite dysplasia, multiple pseudopolyps on index colonoscopy, or a first-degree relative with CRC. There were no differences in colonoscopy quality measures between patients with and without IBD.
CONCLUSIONS: This study stresses the importance of strict short-interval surveillance for IBD patients with high-risk features, including active inflammation on index colonoscopy.

Entities:  

Keywords:  Crohn’s disease; Guidelines; Interval colorectal neoplasia; Surveillance; Ulcerative colitis

Mesh:

Year:  2019        PMID: 31367882      PMCID: PMC6946853          DOI: 10.1007/s10620-019-05754-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  37 in total

1.  European evidence based consensus for endoscopy in inflammatory bowel disease.

Authors:  Vito Annese; Marco Daperno; Matthew D Rutter; Aurelien Amiot; Peter Bossuyt; James East; Marc Ferrante; Martin Götz; Konstantinos H Katsanos; Ralf Kießlich; Ingrid Ordás; Alessandro Repici; Bruno Rosa; Shaji Sebastian; Torsten Kucharzik; Rami Eliakim
Journal:  J Crohns Colitis       Date:  2013-11-01       Impact factor: 9.071

2.  NCCN Clinical Practice Guidelines in Oncology: colon cancer.

Authors:  Paul F Engstrom; Juan Pablo Arnoletti; Al B Benson; Yi-Jen Chen; Michael A Choti; Harry S Cooper; Anne Covey; Raza A Dilawari; Dayna S Early; Peter C Enzinger; Marwan G Fakih; James Fleshman; Charles Fuchs; Jean L Grem; Krystyna Kiel; James A Knol; Lucille A Leong; Edward Lin; Mary F Mulcahy; Sujata Rao; David P Ryan; Leonard Saltz; David Shibata; John M Skibber; Constantinos Sofocleous; James Thomas; Alan P Venook; Christopher Willett
Journal:  J Natl Compr Canc Netw       Date:  2009-09       Impact factor: 11.908

Review 3.  AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease.

Authors:  Francis A Farraye; Robert D Odze; Jayne Eaden; Steven H Itzkowitz
Journal:  Gastroenterology       Date:  2010-02       Impact factor: 22.682

4.  Cancer risk in patients with inflammatory bowel disease: a population-based study.

Authors:  C N Bernstein; J F Blanchard; E Kliewer; A Wajda
Journal:  Cancer       Date:  2001-02-15       Impact factor: 6.860

5.  Impact of physician compliance with colonoscopy surveillance guidelines on interval colorectal cancer.

Authors:  Jennifer Nayor; John R Saltzman; Emily J Campbell; Molly L Perencevich; Kunal Jajoo; James M Richter
Journal:  Gastrointest Endosc       Date:  2016-11-24       Impact factor: 9.427

6.  Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias.

Authors:  Kazuo Konishi; Lanlan Shen; Suna Wang; Stephen J Meltzer; Noam Harpaz; Jean-Pierre J Issa
Journal:  Gastroenterology       Date:  2007-01-25       Impact factor: 22.682

7.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

8.  Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.

Authors:  Stephan Brackmann; Solveig N Andersen; Geir Aamodt; Frøydis Langmark; Ole P F Clausen; Erling Aadland; Olav Fausa; Andreas Rydning; Morten H Vatn
Journal:  Scand J Gastroenterol       Date:  2009       Impact factor: 2.423

9.  Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis.

Authors:  C D Gillen; R S Walmsley; P Prior; H A Andrews; R N Allan
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

10.  Low-grade dysplasia in ulcerative colitis: risk factors for developing high-grade dysplasia or colorectal cancer.

Authors:  Chang-ho Ryan Choi; Ana Ignjatovic-Wilson; Alan Askari; Gui Han Lee; Janindra Warusavitarne; Morgan Moorghen; Siwan Thomas-Gibson; Brian P Saunders; Matthew D Rutter; Trevor A Graham; Ailsa L Hart
Journal:  Am J Gastroenterol       Date:  2015-09-29       Impact factor: 10.864

View more
  5 in total

1.  Comparison of left versus right lateral starting position on colonoscopy: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Daryl Ramai; Jameel Singh; Olivia W Brooks; Mohamed Barakat; Babu P Mohan; Saurabh Chandan; Shahab R Khan; Banreet Dhindsa; Amaninder Dhaliwal; Andrew Ofosu; Douglas G Adler
Journal:  Ann Gastroenterol       Date:  2021-06-03

2.  RING finger 138 deregulation distorts NF-кB signaling and facilities colitis switch to aggressive malignancy.

Authors:  Yalan Lu; Rong Huang; Jianming Ying; Xingchen Li; Tao Jiao; Lei Guo; Haitao Zhou; Han Wang; Amannisa Tuersuntuoheti; Jianmei Liu; Qichen Chen; Yanhong Wang; Luying Su; Changyuan Guo; Fu Xu; Ziyi Wang; Yan Lu; Kai Li; Junbo Liang; Zhen Huang; Xiao Chen; Jinjie Yao; Hanjie Hu; Xiaowen Cheng; Yufeng Wan; Xinyan Chen; Ning Zhang; Shiying Miao; Jianqiang Cai; Linfang Wang; Changzheng Liu; Wei Song; Hong Zhao
Journal:  Signal Transduct Target Ther       Date:  2022-06-13

3.  Patients with inflammatory bowel disease and post-inflammatory polyps have an increased risk of colorectal neoplasia: A meta-analysis.

Authors:  Jia-Ling Shi; Ye-Hong Lv; Jun Huang; Xue Huang; Ying Liu
Journal:  World J Clin Cases       Date:  2022-01-21       Impact factor: 1.337

4.  Colorectal cancer screening and surveillance in patients with inflammatory bowel disease in 2021.

Authors:  Jose Maria Huguet; Luis Ferrer-Barceló; Patrícia Suárez; Eva Sanchez; Jose David Prieto; Victor Garcia; Javier Sempere
Journal:  World J Gastroenterol       Date:  2022-02-07       Impact factor: 5.742

5.  Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease.

Authors:  Claire Gordon; Desmond Chee; Ben Hamilton; Neel M Heerasing; Peter Hendy; Neil Chanchlani; Simeng Lin; Emma Wesley; Ian R Daniels; Nishanthi Silva; Melanie Osborne; Nicholas A Kennedy; James R Goodhand; Tariq Ahmad
Journal:  Aliment Pharmacol Ther       Date:  2020-11-07       Impact factor: 8.171

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.